Advertisement

Applied Microbiology and Biotechnology

, Volume 82, Issue 5, pp 805–813 | Cite as

Engineering of bacterial strains and vectors for the production of plasmid DNA

  • Diana M. Bower
  • Kristala L. J. PratherEmail author
Mini-Review

Abstract

The demand for plasmid DNA (pDNA) is anticipated to increase significantly as DNA vaccines and non-viral gene therapies enter phase 3 clinical trials and are approved for use. This increased demand, along with renewed interest in pDNA as a therapeutic vector, has motivated research targeting the design of high-yield, cost-effective manufacturing processes. An important aspect of this research is engineering bacterial strains and plasmids that are specifically suited to the production of plasmid biopharmaceuticals. This review will survey recent innovations in strain and vector engineering that aim to improve plasmid stability, enhance product safety, increase yield, and facilitate downstream purification. While these innovations all seek to enhance pDNA production, they can vary in complexity from subtle alterations of the host genome or vector backbone to the investigation of non-traditional host strains for higher pDNA yields.

Keywords

Plasmid DNA Escherichia coli DNA vaccines Gene therapy Strain engineering 

Notes

Acknowledgment

Funding for this work was provided by the MIT-Portugal Program.

References

  1. Bi X, Liu LF (1996) A replicational model for DNA recombination between direct repeats. J Mol Biol 256:849–858PubMedGoogle Scholar
  2. Boyd AC, Popp F, Michaelis U, Davidson H, Davidson-Smith H, Doherty A, McLachlan G, Porteous DJ, Seeber S (1999) Insertion of natural intron 6a–6b into a human cDNA-derived gene therapy vector for cystic fibrosis improves plasmid stability and permits facile RNA/DNA discrimination. J Gene Med 1:312–321PubMedGoogle Scholar
  3. Butler VA (1996) Points to consider on plasmid DNA vaccines for preventive infectious disease indications. Center for Biologics Evaluation and Research, Food and Drug Administration. Docket 96N-0400Google Scholar
  4. Carnes AE, Hodgson CP, Williams JA (2006) Inducible Escherichia coli fermentation for increased plasmid DNA production. Biotechnol Appl Biochem 45:155–166PubMedGoogle Scholar
  5. Chen JH, Yeh HT (1997) The seventh copy of IS1 in Escherichia coli W3110 belongs to the IS1 A (IS1E) type which is the only IS1 type that transposes from chromosome to plasmids. Proc Natl Sci Counc Repub China B 21:100–105PubMedGoogle Scholar
  6. Chen ZY, He CY, Kay MA (2005) Improved production and purification of minicircle DNA vector free of plasmid bacterial sequences and capable of persistent transgene expression in vivo. Hum Gene Ther 16:126–131PubMedGoogle Scholar
  7. Ciccolini LAS, Shamlou PA, Titchener-Hooker NJ, Ward JM, Dunnill P (1998) Time course of SDS-alkaline lysis of recombinant bacterial cells for plasmid release. Biotechnol Bioeng 60:768–770PubMedGoogle Scholar
  8. Cooke GD, Cranenburgh RM, Hanak JAJ, Dunnill P, Thatcher DR, Ward JM (2001) Purification of essentially RNA free plasmid DNA using a modified Escherichia coli host strain expressing ribonuclease A. J Biotechnol 85:297–304PubMedGoogle Scholar
  9. Cranenburgh RM, Hanak JA, Williams SG, Sherratt DJ (2001) Escherichia coli strains that allow antibiotic-free plasmid selection and maintenance by repressor titration. Nucleic Acids Res 29:E26PubMedPubMedCentralGoogle Scholar
  10. Cranenburgh RM, Lewis KS, Hanak JA (2004) Effect of plasmid copy number and lac operator sequence on antibiotic-free plasmid selection by operator-repressor titration in Escherichia coli. J Mol Microbiol Biotechnol 7:197–203PubMedGoogle Scholar
  11. Danquah MK, Forde GM (2007) Growth medium selection and its economic impact on plasmid DNA production. J Biosci Bioeng 104:490–497PubMedGoogle Scholar
  12. Darquet AM, Cameron B, Wils P, Scherman D, Crouzet J (1997) A new DNA vehicle for nonviral gene delivery: supercoiled minicircle. Gene Ther 4:1341–1349PubMedGoogle Scholar
  13. Dryselius R, Nekhotiaeva N, Nielsen PE, Good L (2003) Antibiotic-free bacterial strain selection using antisense peptide nucleic acid. BioTechniques 35:1060–1064PubMedGoogle Scholar
  14. Durfee T, Nelson R, Baldwin S, Plunkett III G, Burland V, Mau B, Petrosino JF, Qin X, Muzny DM, Ayele M, Gibbs RA, Csorgo B, Posfai G, Weinstock GM, Blattner FR (2008) The complete genome sequence of Escherichia coli DH10B: insights into the biology of a laboratory workhorse. J Bacteriol 190:2597–2606PubMedPubMedCentralGoogle Scholar
  15. Ferreira GNM, Monteiro GA, Prazeres DMF, Cabral JMS (2000) Downstream processing of plasmid DNA for gene therapy and DNA vaccine applications. Trends Biotechnol 18:380–388PubMedGoogle Scholar
  16. Goh S, Good L (2008) Plasmid selection in Escherichia coli using an endogenous essential gene marker. BMC Biotechnol 8:61PubMedPubMedCentralGoogle Scholar
  17. Green JJ, Zugates GT, Tedford NC, Huang YH, Griffith LG, Lauffenburger DA, Sawicki JA, Langer R, Anderson DG (2007) Combinatorial modification of degradable polymers enables transfection of human cells comparable to adenovirus. Adv Mater 19:2836–2842Google Scholar
  18. Hägg P, de Pohl JW, Abdulkarim F, Isaksson LA (2004) A host/plasmid system that is not dependent on antibiotics and antibiotic resistance genes for stable plasmid maintenance in Escherichia coli. J Biotechnol 111:17–30PubMedGoogle Scholar
  19. Hanke T, McMichael AJ (2000) Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya. Nat Med 6:951–955PubMedGoogle Scholar
  20. Hodgson CP, Williams JA (2006) Improved strains of E. coli for plasmid DNA production. WO 2006/026125 A2Google Scholar
  21. Horn NA, Meek JA, Budahazi G, Marquet M (1995) Cancer gene therapy using plasmid DNA: purification of DNA for human clinical trials. Hum Gene Ther 6:565–573PubMedGoogle Scholar
  22. Kutzler MA, Weiner DB (2008) DNA vaccines: ready for prime time? Nat Rev Genet 9:776–788PubMedPubMedCentralGoogle Scholar
  23. Mairhofer J, Grabherr R (2008) Rational vector design for efficient non-viral gene delivery: challenges facing the use of plasmid DNA. Mol Biotechnol 39:97–104PubMedGoogle Scholar
  24. Mairhofer J, Pfaffenzeller I, Merz D, Grabherr R (2008) A novel antibiotic free plasmid selection system: advances in safe and efficient DNA therapy. Biotechnol J 3:83–89PubMedGoogle Scholar
  25. Mayrhofer P, Blaesen M, Schleef M, Jechlinger W (2008) Minicircle-DNA production by site specific recombination and protein-DNA interaction chromatography. J Gene Med 10:1253–1269PubMedGoogle Scholar
  26. Moore JP, Klasse PJ, Dolan MJ, Ahuja SK (2008) AIDS/HIV. A STEP into darkness or light? Science 320:753–755PubMedGoogle Scholar
  27. Nikaido H (1996) Chapter 5: Outer Membrane. In: Neidhardt F et al (eds) Escherichia coli and Salmonella: cellular and molecular biology, 2nd edn. ASM Press, Washington D.C. Available via EcoSal. http://www.ecosal.org/ecosal/chapters/index.jsp?005. Accessed 20 Jan 2009
  28. NovaRx Corporation (2008) Phase III LucanixTM vaccine therapy in advanced non-small cell lung cancer (NSCLC) following front-line chemotherapy (STOP). In: ClinicalTrials.gov. U.S. National Library of Medicine. http://clinicaltrials.gov/ct2/show/NCT00676507. Accessed 12 Dec 2008
  29. O’Kennedy RD, Baldwin C, Keshavarz-Moore E (2000) Effects of growth medium selection on plasmid DNA production and initial processing steps. J Biotechnol 76:175–183PubMedGoogle Scholar
  30. Okonkowski J, Kizer-Bentley L, Listner K, Robinson D, Chartrain M (2005) Development of a robust, versatile, and scalable inoculum train for the production of a DNA vaccine. Biotechnol Prog 21:1038–1047PubMedGoogle Scholar
  31. Oliveira PH, Lemos F, Monteiro GA, Prazeres DM (2008) Recombination frequency in plasmid DNA containing direct repeats–predictive correlation with repeat and intervening sequence length. Plasmid 60:159–165PubMedGoogle Scholar
  32. Ow DS, Nissom PM, Philp R, Oh SK, Yap MG (2006) Global transcriptional analysis of metabolic burden due to plasmid maintenance in Escherichia coli DH5α during batch fermentation. Enzyme Microb Technol 39:391–398Google Scholar
  33. Ow DS, Lee RM, Nissom PM, Philp R, Oh SK, Yap MG (2007) Inactivating FruR global regulator in plasmid-bearing Escherichia coli alters metabolic gene expression and improves growth rate. J Biotechnol 131:261–269PubMedGoogle Scholar
  34. Ow DS, Yap MG, Oh SK (2009) Enhancement of plasmid DNA yields during fed-batch culture with a fruR-knockout Escherichia coli strain. Biotechnol Appl Biochem 52:53–59PubMedGoogle Scholar
  35. Pan CH, Jimenez GS, Nair N, Wei Q, Adams RJ, Polack FP, Rolland A, Vilalta A, Griffin DE (2008) Use of Vaxfectin adjuvant with DNA vaccine encoding the measles virus hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques against measles virus. Clin Vaccine Immunol 15:1214–1221PubMedPubMedCentralGoogle Scholar
  36. Phue JN, Noronha SB, Hattacharyya R, Wolfe AJ, Shiloach J (2005) Glucose metabolism at high density growth of E. coli B and E. coli K: differences in metabolic pathways are responsible for efficient glucose utilization in E. coli B as determined by microarrays and Northern blot analyses. Biotechnol Bioeng 90:805–820PubMedGoogle Scholar
  37. Phue JN, Lee SJ, Trinh L, Shiloach J (2008) Modified Escherichia coli B (BL21), a superior producer of plasmid DNA compared with Escherichia coli K (DH5alpha). Biotechnol Bioeng 101:831–836PubMedGoogle Scholar
  38. Pogliano J (2002) Dynamic cellular location of bacterial plasmids. Curr Opin Microbiol 5:586–590PubMedGoogle Scholar
  39. Posfai G, Plunkett III G, Feher T, Frisch D, Keil GM, Umenhoffer K, Kolisnychenko V, Stahl B, Sharma SS, de Arruda M, Burland V, Harcum SW, Blattner FR (2006) Emergent properties of reduced-genome Escherichia coli. Science 312:1044–1046PubMedGoogle Scholar
  40. Prather KL, Edmonds MC, Herod JW (2006) Identification and characterization of IS1 transposition in plasmid amplification mutants of E. coli clones producing DNA vaccines. Appl Microbiol Biotechnol 73:815–826PubMedGoogle Scholar
  41. Prazeres DMF, Ferreira GNM (2004) Design of flowsheets for the recovery and purification of plasmids for gene therapy and DNA vaccination. Chem Eng Process 43:609–624Google Scholar
  42. Ribeiro SC, Oliveira PH, Prazeres DM, Monteiro GA (2008) High frequency plasmid recombination mediated by 28 bp direct repeats. Mol Biotechnol 40:252–260PubMedGoogle Scholar
  43. Sanofi-Aventis (2008) Efficacy and safety of XRP0038/NV1FGF in critical limb ischemia patients with skin lesions (TAMARIS). In: ClinicalTrials.gov. U.S. National Library of Medicine. http://clinicaltrials.gov/ct2/show/NCT00566657. Accessed 12 Dec 2008
  44. Schneider D, Duperchy E, Depeyrot J, Coursange E, Lenski R, Blot M (2002) Genomic comparisons among Escherichia coli strains B, K-12, and O157:H7 using IS elements as molecular markers. BMC Microbiol 2:18PubMedPubMedCentralGoogle Scholar
  45. Soubrier F, Cameron B, Manse B, Somarriba S, Dubertret C, Jaslin G, Jung G, Caer CL, Dang D, Mouvault JM, Scherman D, Mayaux JF, Crouzet J (1999) pCOR: a new design of plasmid vectors for nonviral gene therapy. Gene Ther 6:1482–1488PubMedGoogle Scholar
  46. Soubrier F, Laborderie B, Cameron B (2005) Improvement of pCOR plasmid copy number for pharmaceutical applications. Appl Microbiol Biotechnol 66:683–688PubMedGoogle Scholar
  47. Summers D (1998) Timing, self-control and a sense of direction are the secrets of multicopy plasmid stability. Mol Microbiol 29:1137–1145PubMedPubMedCentralGoogle Scholar
  48. Szpirer CY, Milinkovitch MC (2005) Separate-component-stabilization system for protein and DNA production without the use of antibiotics. BioTechniques 38:775–781PubMedGoogle Scholar
  49. Tolmachov O, Palaszewski I, Bigger B, Coutelle C (2006) RecET driven chromosomal gene targeting to generate a RecA deficient Escherichia coli strain for Cre mediated production of minicircle DNA. BMC Biotechnol 6:17PubMedPubMedCentralGoogle Scholar
  50. Twiss E, Coros AM, Tavakoli NP, Derbyshire KM (2005) Transposition is modulated by a diverse set of host factors in Escherichia coli and is stimulated by nutritional stress. Mol Microbiol 57:1593–1607PubMedGoogle Scholar
  51. Vical (2008) A Phase 3 pivotal trial comparing Allovectin-7® alone vs. chemotherapy alone in patients with stage 3 or stage 4 melanoma. In: ClinicalTrials.gov. U.S. National Library of Medicine. http://clinicaltrials.gov/ct2/show/NCT00395070. Accessed 12 Dec 2008
  52. Vidal L, Pinsach J, Striedner G, Caminal G, Ferrer P (2008) Development of an antibiotic-free plasmid selection system based on glycine auxotrophy for recombinant protein overproduction in Escherichia coli. J Biotechnol 134:127–136PubMedGoogle Scholar
  53. Wang Z, Le G, Shi Y, Wegrzyn G (2001) Medium design for plasmid DNA production based on stoichiometric model. Process Biochem 36:1085–1093Google Scholar
  54. Yau SY, Keshavarz-Moore E, Ward J (2008) Host strain influences on supercoiled plasmid DNA production in Escherichia coli: Implications for efficient design of large-scale processes. Biotechnol Bioeng 101:529–544PubMedGoogle Scholar
  55. Zhao JB, Wei DZ, Tong WY (2007) Identification of Escherichia coli host cell for high plasmid stability and improved production of antihuman ovarian carcinoma x antihuman CD3 single-chain bispecific antibody. Appl Microbiol Biotechnol 76:795–800PubMedGoogle Scholar
  56. Zielenkiewicz U, Ceglowski P (2001) Mechanisms of plasmid stable maintenance with special focus on plasmid addiction systems. Acta Biochim Pol 48:1003–1023PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  1. 1.Department of Chemical EngineeringMassachusetts Institute of TechnologyCambridgeUSA

Personalised recommendations